The lawsuit, filed in the U.S. District Court for the Northern District of California under the caption Robbins v. GRAIL, Inc., et al., claims the company violated federal securities laws by misrepresenting the design and potential success of the NHS-Galleri trial. While GRAIL touted the trial as a key milestone for its early cancer detection technology, the complaint asserts that the three-year timeframe was fundamentally insufficient to achieve the stated goal of reducing late-stage cancer diagnoses.

The market reaction was swift following the February 19, 2026, disclosure that the trial’s primary endpoint—a statistically significant reduction in Stage III-IV cancers—was not achieved. GRAIL shares plummeted from $101.53 to $50.21 the following day. Bleichmar Fonti & Auld LLP, the firm representing the class, has set an August 4, 2026, deadline for investors to petition the court for lead plaintiff status.